SLC5A2 and diabetes mellitus: The long-term efficacy of sodium–glucose cotransporter 2 (SGLT-2) inhibitors in managing type 2 diabetes mellitus (T2DM) extends beyond glycemic control, with growing evidence supporting their role in reducing long-term cardiovascular and renal complications.